Drug Detail

Information about AMG 510

Generic Name
IND	AMG 510
Brand Name (US)
Manufacturer	Amgen
Drug Type
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy
Strategy
Drug Category	KRAS inhibitor

KRAS mutations are one of the most common mutations in cancer. However, it has been very difficult to develop effective drugs that inhibit KRAS. AMG 510 is showing promising results in phase I clinical trials (2019 ASCO and see link below).
A particular mutation, KRASG12C is mentioned on the Amgen website and seems to be the primary target of this drug. It's too early to say if it will inhibit other KRAS mutations as well (information is limited at this time, 2019).